Literature DB >> 19070525

Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children.

Carlos G Teran1, Carlos N Teran-Escalera, Patricia Villarroel.   

Abstract

BACKGROUND: In previous studies, nitazoxanide has demonstrated a cytoprotective effect against rotavirus, reducing the duration of diarrhea in comparison to placebo. We designed a randomized, single-blind, controlled trial in order to assess the effectiveness of nitazoxanide and probiotics in comparison with a control group.
METHODS: Seventy-five children aged from 28 days to 24 months, with rotavirus diarrhea, were randomly assigned to receive either oral nitazoxanide (15 mg/kg/day) twice a day for three days, a combination of oral probiotics, 1 g twice a day for five days, or only oral or systemic rehydration solutions. The duration of diarrhea and of hospitalization were the primary outcome measures, and daily stool frequency, vomiting, and fever were some of the secondary outcome measures analyzed.
RESULTS: The median duration of hospitalization was significantly shorter (p = 0.017) in patients who received nitazoxanide (81 h) and probiotics (72 h) compared to patients who received oral rehydration solution alone (108 h). Similarly, the median duration of diarrhea was significantly reduced (p = 0.009) in children who received nitazoxanide (54 h) and probiotics (48 h) compared to the control group (79 h).
CONCLUSIONS: Treatment with nitazoxanide and probiotics is effective in the management of children with acute rotavirus diarrhea. Small differences in favor of nitazoxanide were found in comparison with probiotics. Nitazoxanide is an important treatment option for rotavirus diarrhea.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070525     DOI: 10.1016/j.ijid.2008.09.014

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  34 in total

1.  Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea.

Authors:  Fangning Liu; Ke Wen; Guohua Li; Xingdong Yang; Jacob Kocher; Tammy Bui; Dorothy Jones; Kevin Pelzer; Sherrie Clark-Deener; Lijuan Yuan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-02       Impact factor: 2.839

2.  Astrovirus Replication Is Inhibited by Nitazoxanide In Vitro and In Vivo.

Authors:  Virginia Hargest; Bridgett Sharp; Brandi Livingston; Valerie Cortez; Stacey Schultz-Cherry
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Label-free chemiresistive immunosensors for viruses.

Authors:  Dhammanand J Shirale; Mangesh A Bangar; Miso Park; Marylynn V Yates; Wilfred Chen; Nosang V Myung; Ashok Mulchandani
Journal:  Environ Sci Technol       Date:  2010-11-08       Impact factor: 9.028

4.  Porcine small intestinal epithelial cell line (IPEC-J2) of rotavirus infection as a new model for the study of innate immune responses to rotaviruses and probiotics.

Authors:  Fangning Liu; Guohua Li; Ke Wen; Tammy Bui; Dianjun Cao; Yanming Zhang; Lijuan Yuan
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

Review 5.  Options for improving effectiveness of rotavirus vaccines in developing countries.

Authors:  Marion S Tissera; Daniel Cowley; Nada Bogdanovic-Sakran; Melanie L Hutton; Dena Lyras; Carl D Kirkwood; Jim P Buttery
Journal:  Hum Vaccin Immunother       Date:  2016-11-11       Impact factor: 3.452

6.  Lactobacillus rhamnosus GG on rotavirus-induced injury of ileal epithelium in gnotobiotic pigs.

Authors:  Fangning Liu; Guohua Li; Ke Wen; Shaoping Wu; Yongguo Zhang; Tammy Bui; Xingdong Yang; Jacob Kocher; Jun Sun; Bernard Jortner; Lijuan Yuan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-12       Impact factor: 2.839

7.  Treatment and prevention of rotavirus infection in children.

Authors:  Penelope H Dennehy
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

8.  Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation.

Authors:  Simone La Frazia; Alessandra Ciucci; Francesca Arnoldi; Maurizio Coira; Patrizia Gianferretti; Mara Angelini; Giuseppe Belardo; Oscar R Burrone; Jean-Francois Rossignol; M Gabriella Santoro
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

9.  A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis.

Authors:  M Rigo-Adrover; S Saldaña-Ruíz; K van Limpt; K Knipping; J Garssen; J Knol; A Franch; M Castell; F J Pérez-Cano
Journal:  Eur J Nutr       Date:  2016-04-25       Impact factor: 5.614

10.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.